Diagnostic Center | September 01, 2022
Daiichi Sankyo announces initiation of Phase 3 Trial of mRNA
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
Complaints to be filed in both United States and Germany alleging that Pfizer and BioNTech's COVID-19 vaccine Comirnaty unlawfully infringes patents Moderna filed between 2010 and 2016
Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small
Company is investing more than €100 million in the expansion of the Halle site
It is a two dose vaccine to be administered intramuscularly at 28 days apart
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
University of Pennsylvania scientists Katalin Karikó and Drew Weissman to be honoured at June 7 symposium in New York City for their research that enabled Covid-19 vaccines
Subscribe To Our Newsletter & Stay Updated
